Based on Volume Watch Todays Profitable Stock ( XLF, FB, PFE, LLY )

Los Angelas, CA -- (SBWIRE) -- 10/03/2012 -- SPDR Select Secto (PCX:XLF) is +0.03 - +0.19% from the previous close of $15.66. It traded between $15.62 - 15.76 with total traded volume of 43878448 shares. Keep a close eye on XLF, as the stock has been showing unusual moves over the past weeks. At Current market price, XLF has recovered +36.79% from its 52-week Low of 11.47 and has Pulled back -4.56% from its 52-week high of 16.44. Select Financial Sector SPDRs ( XLF ) is up 0.7%. Direxion Daily Financial Bull 3X shares (FAS) is up 1.6%. Its bearish counterpart, FAZ, is down 1.3%. Among financial actives, MGIC Investment Corp. (MTG) is up 16% after Freddie Mac late Friday cut the mortgage insurer's capital requirements by half to $100 million. The government housing-finance body also approved MTG's underwriting unit to again sell coverage in 16 jurisdictions excluding its home state of Wisconsin, pending resolution of a dispute over covered mortgages. The company has until Oct. 31 to resolve the dispute with the agency to retain its authority to issue mortgage insurance.

Are these stocks a buy or sell? Find Out Here

Facebook, Inc. (NasdaqNM:FB) is very active today and traded between $21.82 - 22.49 with total traded volume of 29341392 shares. At a current price of 22.27, FB is +0.28 - +1.27% from the previous close of $21.99. Moreover, At Current Market Price, FB is in distance of +9.95% from its 50-day Moving Average price of $20.254 and -12.30% from its 200-day Moving Average price of $25.3931. Facebook, Inc. (NASDAQ: FB) is engaged in building products to create utility for users, developers, and advertisers. People use Facebook to stay connected with their friends and family, to discover what is going on in the world around them, and to share and express what matters to them to the people they care about. Developers can use the Facebook Platform to build applications and Websites that integrate with Facebook to reach its global network of users and to build personalized and social products. Advertisers can engage with more than 900 million monthly active users (MAUs) on Facebook or subsets of its users based on information they have chosen to share with the Company, such as their age, location, gender, or interests. It offers advertisers a combination of reach, relevance, social context and engagement.

Are these stocks a buy or sell? Find Out Here

Pfizer, Inc. Comm (NYSE:PFE) reported EPS of 1.334. For the Current Fiscal year, the company is expected to report EPS of 2.21. For the Next Quarter and Next Year, the company is expected to report EPS of 0.49 and 2.32 respectively. At Current Market Price, PFE is in distance of +3.87% from its 50-day Moving Average price of $24.1846 and +8.99% from its 200-day Moving Average price of $23.0485. Pfizer (PFE) has long been a Wall Street favorite and it is a Dow 30 component. The future for PFE as is the future for all drug companies is dependent on the ability of the company to bring new patentable products into the product pipeline as some of their old patents expire. The market has predicted that they will be able to do that and after a better than expected earnings report the stock has seen a nice gain as is evidenced.

Are these stocks a buy or sell? Find Out Here

Eli Lilly and Com (NYSE:LLY) reported EPS of 3.609. For the Current Fiscal year, the company is expected to report EPS of 3.39. For the Next Quarter and Next Year, the company is expected to report EPS of 0.83 and 3.77 respectively. At Current Market Price, LLY is in distance of +5.28% from its 50-day Moving Average price of $45.5377 and +12.58% from its 200-day Moving Average price of $42.5818. Eli Lilly and Company (NYSE: LLY) announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC). Results were presented today during the Lung Cancer - Metastatic Poster Session at the ESMO 2012 Congress (European Society for Medical Oncology), 1:00 p.m. - 2:00 p.m. CET, in Vienna, Austria. Interim data for a study in chemotherapy-näive patients with advanced NSCLC treated with ramucirumab in combination with first-line ALIMTA® (pemetrexed for injection)/platinum-based chemotherapy (Abstract #1245) and final data for a study in patients treated with ramucirumab in combination with paclitaxel/ carboplatinum chemotherapy (Abstract#1287) were presented. The pre-specified interim analysis of progression-free survival (PFS) (Abstract #1245) and final six-month PFS rate (Abstract #1287) support continued development of ramucirumab in lung cancer.

Are these stocks a buy or sell? Find Out Here

Disclaimer:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com